BioCentury
ARTICLE | Financial News

Amicus plummets on data for Fabry's compound

December 21, 2012 2:06 AM UTC

Amicus Therapeutics Inc. (NASDAQ:FOLD) fell $2.71 (47%) to $3.06 on Thursday after the company and partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said late Wednesday that Amigal migalastat missed the...